<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04636502</url>
  </required_header>
  <id_info>
    <org_study_id>PID-4001</org_study_id>
    <nct_id>NCT04636502</nct_id>
  </id_info>
  <brief_title>Retrospective, Observational Chart Review Study Conducted in Poland to Document the Management and Clinical Outcome of CUVITRU and HYQVIA in Pediatric Participants (&lt; 18 Years) With Primary Immunodeficiency (PID)</brief_title>
  <acronym>IG-TATRY</acronym>
  <official_title>Subcutaneous Immune Globulin (SCIG 20%) and Facilitated Subcutaneous Immunoglobulin (fSCIG) Treatment in Polish Paediatric Patients With Primary Immunodeficiencies (PID) - Retrospective Medical Chart Review Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <brief_summary>
    <textblock>
      The purpose of this observational, multi-center, retrospective cohort study is to assess&#xD;
      treatment patterns of Cuvitru (SCIG) 20 percent (%) and HyQvia (fSCIG) in polish pediatric&#xD;
      participants with PID. The study will collect pediatric patient data. These data are gathered&#xD;
      and collected during routine clinical care. As this is a non-interventional/observational&#xD;
      study, no treatment/pharmacotherapy is provided as part of the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subcutaneous immune globulin (SCIG 20%) and facilitated subcutaneous immunoglobulin (fSCIG)&#xD;
      treatment in Polish paediatric patients with primary immunodeficiencies (PID) - retrospective&#xD;
      medical chart review study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 8, 2021</start_date>
  <completion_date type="Actual">September 14, 2021</completion_date>
  <primary_completion_date type="Actual">September 14, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Doses per Infusion</measure>
    <time_frame>From start of the study upto end of the study (6 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Infusion Sites</measure>
    <time_frame>From start of the study upto end of the study (6 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion Volume</measure>
    <time_frame>From start of the study upto end of the study (6 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Method of Administration</measure>
    <time_frame>From start of the study upto end of the study (6 months)</time_frame>
    <description>Method of administration in participants will be through pump or rapid push.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Length of Needle</measure>
    <time_frame>From start of the study upto end of the study (6 months)</time_frame>
    <description>Length of needle used for infusions will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Person who Perform the Infusion</measure>
    <time_frame>From start of the study upto end of the study (6 months)</time_frame>
    <description>Assessment of person (parent/guardian or self) who performs the infusion will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Type of Pump</measure>
    <time_frame>From start of the study upto end of the study (6 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Dose per 4 weeks</measure>
    <time_frame>From start of the study upto end of the study (6 months)</time_frame>
    <description>Total dose administered per 4 weeks data will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Infusion Volume per 4 Weeks</measure>
    <time_frame>From start of the study upto end of the study (6 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Interval per 4 Weeks</measure>
    <time_frame>From start of the study upto end of the study (6 months)</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">96</enrollment>
  <condition>Primary Immunodeficiencies (PID)</condition>
  <arm_group>
    <arm_group_label>Cohort</arm_group_label>
    <description>Participants who had treated with fSCIG (HyQvia) for not more than 27 months and SCIG 20% (Cuvitru) for not more than 35 months.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with PID on treatment with SCIG 20% or fSCIG will be included in this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participant eligibility is determined according to the following criteria prior to entry&#xD;
        into the study:&#xD;
&#xD;
          -  The participant or, when applicable, the participant's legally acceptable&#xD;
             representative signs and dates a written, informed consent form and any required&#xD;
             privacy authorization prior to the initiation of any study procedures.&#xD;
&#xD;
          -  Male or female participants with PID, aged less than (&lt;)18 years treated with SCIG 20%&#xD;
             or fSCIG..&#xD;
&#xD;
          -  Diagnosis of PID according to the criteria developed by the European Society for&#xD;
             Immunodeficiencies (ESID) https://esid.org/About-ESID&#xD;
&#xD;
          -  Treatment period for 20% SCIG ranges from November 1, 2017 until June 30, 2020, and&#xD;
             for fSCIG from July 1, 2018 until June 30, 2020.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Dziecięcy w Krakowie</name>
      <address>
        <city>Kraków</city>
        <zip>30-663</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut &quot;Pomnik - Centrum Zdrowia Dziecka&quot;</name>
      <address>
        <city>Warszawa</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny im. J. Gromkowskiego</name>
      <address>
        <city>Wrocław</city>
        <zip>51-149</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 1 im. prof. Stanisława Szyszko Śląskiego Uniwersytetu Medycznego w Katowicach</name>
      <address>
        <city>Zabrze</city>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.takeda.com/study-detail/5fb63601d98d000029649dce</url>
    <description>To obtain more information on the study, click here/on this link</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 18, 2020</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Immunodeficiency Diseases</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

